2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John H. Strickler, MD, discusses factors to consider when selecting between trifluridine/tipiracil and regorafenib for the treatment of patients with colorectal cancer.
John H. Strickler, MD, medical oncologist at Duke Cancer Center, Duke Health, discusses factors to consider when selecting between trifluridine/tipiracil (Lonsurf; TAS-102) and regorafenib (Stivarga) for the treatment of patients with colorectal cancer.
Often, the decision between with the 2 agents is based on the individual patient, Strickler says. For example, if a patient has not received recent cytotoxic chemotherapy and has adequate kidney and liver function, TAS-102 with or without bevacizumab (Avastin) might be the stronger option, Strickler explains. If a patient has been heavily pretreated with cytotoxic chemotherapy and you are considering the benefit of a different mechanism of action, regorafenib may be a more beneficial choice in the third-line setting, Strickler notes.
Ultimately, the goal is to match the patient with the agent that will provide the most clinical benefit with a manageable safety profile, Strickler says. Treatment for these patients is not a one-size-fits-all approach, Strickler concludes.